Isotretinoin

In a five‑year retrospective cohort of acne patients treated with moderate cumulative isotretinoin doses, the drug was generally well tolerated and effective, though clinically relevant disturbances in lipid profile and prolactin were frequent, supporting the need for routine lipid and endocrine monitoring.

In otherwise healthy patients with moderate to severe acne, low-dose isotretinoin regimens achieved approximately 90% clinical efficacy with markedly reduced lesion counts, while the most common adverse effect was cheilitis and only a small proportion showed mild, reversible elevations in liver enzymes and serum lipids.

A decade of clinical experience in large numbers of acne patients showed that isotretinoin provided highly effective, long-term control of severe acne and was generally safe when used with appropriate dosing and monitoring, with adverse events largely limited to expected mucocutaneous and laboratory changes.

In a five‑year retrospective cohort of acne patients treated with moderate cumulative isotretinoin doses, the drug was generally well tolerated and effective, though clinically relevant disturbances in lipid profile and prolactin were frequent, supporting the need for routine lipid and endocrine monitoring.

A decade of clinical experience in large numbers of acne patients showed that isotretinoin provided highly effective, long-term control of severe acne and was generally safe when used with appropriate dosing and monitoring, with adverse events largely limited to expected mucocutaneous and laboratory changes.

In otherwise healthy patients with moderate to severe acne, low-dose isotretinoin regimens achieved approximately 90% clinical efficacy with markedly reduced lesion counts, while the most common adverse effect was cheilitis and only a small proportion showed mild, reversible elevations in liver enzymes and serum lipids.

In a five‑year retrospective cohort of acne patients treated with moderate cumulative isotretinoin doses, the drug was generally well tolerated and effective, though clinically relevant disturbances in lipid profile and prolactin were frequent, supporting the need for routine lipid and endocrine monitoring.

In otherwise healthy patients with moderate to severe acne, low-dose isotretinoin regimens achieved approximately 90% clinical efficacy with markedly reduced lesion counts, while the most common adverse effect was cheilitis and only a small proportion showed mild, reversible elevations in liver enzymes and serum lipids.

A decade of clinical experience in large numbers of acne patients showed that isotretinoin provided highly effective, long-term control of severe acne and was generally safe when used with appropriate dosing and monitoring, with adverse events largely limited to expected mucocutaneous and laboratory changes.

This review of human studies reported that isotretinoin therapy in acne patients induces changes in hematologic, metabolic, and endocrine parameters and can influence mood, but large observational analyses did not find an overall increase in psychiatric disorders and in some matched cohorts isotretinoin users had lower rates of anxiety, sleep problems, self‑harm, and psychotropic medication use compared with those treated with oral antibiotics.

In a five‑year retrospective cohort of acne patients treated with moderate cumulative isotretinoin doses, the drug was generally well tolerated and effective, though clinically relevant disturbances in lipid profile and prolactin were frequent, supporting the need for routine lipid and endocrine monitoring.

Pooling data from multiple clinical trials in acne patients, this meta‑analysis identified a broad spectrum of isotretinoin‑related adverse events, with very high rates of mucocutaneous changes and additional ophthalmic, musculoskeletal, gastrointestinal, neurological, infectious, and laboratory abnormalities, most of which were reversible after treatment cessation.

In otherwise healthy patients with moderate to severe acne, low-dose isotretinoin regimens achieved approximately 90% clinical efficacy with markedly reduced lesion counts, while the most common adverse effect was cheilitis and only a small proportion showed mild, reversible elevations in liver enzymes and serum lipids.

Pooling data from multiple clinical trials in acne patients, this meta‑analysis identified a broad spectrum of isotretinoin‑related adverse events, with very high rates of mucocutaneous changes and additional ophthalmic, musculoskeletal, gastrointestinal, neurological, infectious, and laboratory abnormalities, most of which were reversible after treatment cessation.

In otherwise healthy patients with moderate to severe acne, low-dose isotretinoin regimens achieved approximately 90% clinical efficacy with markedly reduced lesion counts, while the most common adverse effect was cheilitis and only a small proportion showed mild, reversible elevations in liver enzymes and serum lipids.

Pooling data from multiple clinical trials in acne patients, this meta‑analysis identified a broad spectrum of isotretinoin‑related adverse events, with very high rates of mucocutaneous changes and additional ophthalmic, musculoskeletal, gastrointestinal, neurological, infectious, and laboratory abnormalities, most of which were reversible after treatment cessation.

Pooling data from multiple clinical trials in acne patients, this meta‑analysis identified a broad spectrum of isotretinoin‑related adverse events, with very high rates of mucocutaneous changes and additional ophthalmic, musculoskeletal, gastrointestinal, neurological, infectious, and laboratory abnormalities, most of which were reversible after treatment cessation.

Pooling data from multiple clinical trials in acne patients, this meta‑analysis identified a broad spectrum of isotretinoin‑related adverse events, with very high rates of mucocutaneous changes and additional ophthalmic, musculoskeletal, gastrointestinal, neurological, infectious, and laboratory abnormalities, most of which were reversible after treatment cessation.